Visit the Website for Patients
In Partnership With
About Us
Contact
Français
Visit the Website for Patients
Accelerate Your Clinical
Research Projects
Accelerate Your Clinical
Research Projects
Efficient Regulatory Assessment
Clinical Trial Drug Authorization Process
Medical Device Authorization Process
Medical Device Classification Tool
Streamlined Operational Feasibility
Accelerate the Execution of Your Confidential Disclosure Agreement (CDA)
Directory of Treatment Guidelines
FAST TRACK Your Site Startup
Find the Expertise
You Need
Find the Expertise
You Need
Clinical Sites
Directory of Health Institutions
Directory of Private Clinics
Biotechnology Service Providers
Directory of Biotechnology Service Providers
Patient Organizations
Directory of Patient Organizations
Quebec’s Clinical Trials Database
Access to Centralized
Quebec Health Data
Access to Centralized
Quebec Health Data
Health Data Available Without Access Request
Health Data Available Upon Request to the Research Access Center (RAC)
Bring Your Innovations
to Market
Set up Your Company in Quebec
About Us
Contact
Français
Home
Accelerate Your Clinical Research Projects
Clinical Trial Evaluation
Approval Performances
Approval Performances
Filters
(0)
Medical condition
Uncontrolled Asthma
ASCVD and Obesity
Adolescents MS
Advanced Malignant Tumors
Advanced Solid Tumors
Advanced Solid Tumours
Arthritis
Asthma
Auto-immune Diseases
Autoimmune Disease
Breast Cancer
Cardiology
Celiac Disease
Chronic Hepatitis B
Chronic Inflammatory Demyelinating Polyneuropathy (CIDP)
Chronic Kidney Disease and High Blood Pressure
Chronic Rhinosinusitis
Chronic Rhinosinusitis with Nasal Polyps
Colorectal Cancer
Extensive-Stage Small Cell Lung Cancer
Focal Segmental Glomerulosclerosis (FSGS)
Graft Versus Host Disease
Graves' disease
HER2 Solid Tumors
HIV
HIV / Hepatitis B
HIV-1
Head and Neck Cancer
Heart Failure
Hematology – Von Willebrand Disease
Hepatocellular Carcinoma
Lung Cancer
Lupus
Lymphome
Multiple Myeloma
Multiple Sclerosis
Myeloma
Nasal Polyps with Asthma
Neurology
Non-Small Cell Cancer (NSCLC)
Non-Small Cell Lung Cancer (NSCLC)
Obesity
Obesity and Heart Failure
Oncology: GEP-NET
Pancreatic, Lung, Breast and Colorectal Cancers
Progressive Multiple Sclerosis (PMS)
Prostate Cancer
Pulmonary Disease
Rare Disease
Relapsed or Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome
Scleroderma
Solid Tumors
Spinal Muscular Atrophy
Type 1 Diabetes
Ulcerative Colitis
Urticaire
Phase
Phase I
Phase I/II
Phase I/Ib
Phase IA
Phase II
Phase II/III
Phase III
Phase IIIb
Phase IIb
Phase Non-Interventional
Authorization time
Less than 8 weeks
8 to 12 weeks
More than 12 weeks
Site ranking
1st site activated in Canada
1st site activated worldwide
Canadian FPI
FPI globally
Top 3 activated sites in Canada
Top 3 activated sites worldwide
Year
2025
2024
2023
2022
2021
Apply filters
85-87 of 87 results
Clear filters
ONWARDS
Arthritis
Phase II
9.1 weeks
Ongoing study
Read the news
PKM16982
Urticaire
Phase III
8.4 weeks
2nd site activated in Canada
STRENGTH
Spinal Muscular Atrophy
Phase II
12.1 weeks
1st site activated in Canada
Read the news
« Previous
1
2
…
7
8
Subscribe to our newsletter!
Follow the latest news from CATALIS and Clinical Trials Quebec